MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/2767-9764.crc-22-0278

Медицинская библиотека · Cancer research communications · 2023

Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling.

Matos Israel, Barvalia Maunish, Chehal Manreet K, Robertson A Gordon, Kulic Iva, Silva Jessica A F D, Ranganathan Abhinandan, Short Amy, Huang Yu-Hsuan, Long Erin, Priatel John J, Dhanji Salim, Nelson Brad H, Krebs Danielle L, Harder Kenneth W

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

UNLABELLED: While immunotherapies such as immune checkpoint blockade and adoptive T-cell therapy improve survival for a subset of human malignancies, many patients fail to respond. Phagocytes including dendritic cells (DC), monocytes, and macrophages (MF) orchestrate innate and adaptive immune responses against tumors. However, tumor-derived factors may limit immunotherapy effectiveness by altering phagocyte signal transduction, development, and activity. Using Cytometry by Time-of-Flight, we found that tumor-derived GCSF altered myeloid cell distribution both locally and systemically. We distinguished a large number of GCSF-induced immune cell subset and signal transduction pathway perturbations in tumor-bearing mice, including a prominent increase in immature neutrophil/myeloid-derived suppressor cell (Neut/MDSC) subsets and tumor-resident PD-L1+ Neut/MDSCs. GCSF expression was also linked to distinct tumor-associated MF populations, decreased conventional DCs, and splenomegaly characterized by increased splenic progenitors with diminished DC differentiation potential. GCSF-dependent dysregulation of DC development was recapitulated in bone marrow cultures in vitro, using medium derived from GCSF-expressing tumor cell cultures. Importantly, tumor-derived GCSF impaired T-cell adoptive cell therapy effectiveness and was associated with increased tumor volume and diminished survival of mice with mammary cancer. Treatment with neutralizing anti-GCSF antibodies reduced colonic and circulatory Neut/MDSCs, normalized colonic immune cell composition and diminished tumor burden in a spontaneous model of mouse colon cancer. Analysis of human colorectal cancer patient gene expression data revealed a significant correlation between survival and low GCSF and Neut/MDSC gene expression. Our data suggest that normalizing GCSF bioactivity may improve immunotherapy in cancers associated with GCSF overexpression.

SIGNIFICANCE: Tumor-derived GCSF leads to systemic immune population changes. GCSF blockade restores immune populations, improves immunotherapy, and reduces tumor size, paralleling human colorectal cancer data. GCSF inhibition may synergize with current immunotherapies to treat GCSF-secreting tumors.

Для цитирования: Matos Israel, Barvalia Maunish, Chehal Manreet K, Robertson A Gordon, Kulic Iva, Silva Jessica A F D, Ranganathan Abhinandan, Short Amy, Huang Yu-Hsuan, Long Erin, Priatel John J, Dhanji Salim, Nelson Brad H, Krebs Danielle L, Harder Kenneth W. Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling.. Cancer research communications. 2023. DOI: 10.1158/2767-9764.crc-22-0278.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.